GeneDx Holdings Corp. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The company was formerly Sema4 Holdings Corp.; it acquired Legacy GeneDx on April 29, 2022 and changed its name to GeneDx Holdings Corp. on January 9, 2023. Results include GeneDx only from the acquisition date, so year-over-year comparisons are not fully comparable.
Business context and strategic direction
GeneDx is refocusing on pediatric and rare-disease diagnostics, particularly whole-exome and whole-genome sequencing, alongside its Centrellis health-data platform. It exited somatic tumor testing in the fourth quarter of 2022 and completed its exit from reproductive and women’s health testing in the first quarter of 2023. The company plans to consolidate testing at its Gaithersburg, Maryland laboratory.
Financial and operating highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $234.7 million | $212.2 million |
| Diagnostic test revenue | $227.3 million | $205.1 million |
| Gross loss / margin | $(26.8) million / (11%) | $(16.6) million / (8%) |
| Net loss | $(549.0) million | $(245.4) million |
| Net cash used in operations | $(319.2) million | $(190.4) million |
| Cash and cash equivalents at year-end | $123.9 million | $400.6 million |
- Revenue grew 11%, reflecting $114.9 million of acquired GeneDx diagnostic revenue from the acquisition date, partly offset by a $92.6 million decline in Legacy Sema4 diagnostics. Legacy Sema4’s decline included discontinued COVID-19 testing, payer denials, and revenue adjustments.
- GAAP operating loss was $667.7 million, including a $210.1 million impairment charge. Net loss also reflected a $49.1 million income tax benefit and $69.6 million of net other income, including non-cash fair-value gains on warrant and contingent liabilities.
- Adjusted gross margin, a non-GAAP measure, fell to 5% from 9%. Adjusted EBITDA loss, also non-GAAP, widened to $317.0 million from $199.6 million.
- Cash, cash equivalents, and restricted cash totaled $138.3 million at year-end; restricted cash included $13.5 million held in acquisition-related escrow. Investing activities used $141.3 million, including $127.0 million net cash paid for the GeneDx acquisition.
- Year-end debt included $11.0 million under the Connecticut DECD loan. The $125 million SVB revolving credit facility was undrawn at year-end. Lease liabilities were $66.1 million, with $140.9 million in undiscounted future minimum lease payments.
- Management stated that cash and cash equivalents were expected to fund operations for at least 12 months from the filing date. In January 2023, the company raised approximately $150 million gross, or $137.6 million net, through equity offerings; additional net proceeds of $7.6 million were expected upon issuance of shares pending stockholder approval.
- Test volumes were 528,876 in 2022 versus approximately 709,942 in Legacy Sema4 laboratories in 2021. The decrease primarily reflected exits from COVID-19, somatic oncology, and reproductive health testing.
Material changes, outlook, and notable items
- The strategic exits involved workforce reductions and restructuring: approximately 250 positions were eliminated in 2022, with approximately 500 additional positions associated with the reproductive-health exit. Combined reductions were approximately 32.5% of the workforce. Management expected further exit and restructuring charges; actual costs may differ from estimates.
- The company recorded $54.0 million of 2022 revenue reductions from changes in estimated variable consideration, including payer-related adjustments. A payer settlement calls for $42.0 million in installments through June 2026; $15.0 million was paid in December 2022, and $39.0 million was accrued at year-end for the settlement and potential recoupments.
- The $210.1 million impairment included a full $174.5 million write-off of acquisition goodwill and a $22.5 million inventory impairment related to discontinued businesses. The company also recorded a $10.0 million impairment on excess office space and accelerated $24.0 million of depreciation and amortization due to revised useful lives of certain assets. These items are not all components of the same impairment line.
- Legacy GeneDx acquisition consideration included up to $150 million in revenue-based milestone payments. The 2022 milestone was achieved and was expected to be settled primarily in shares; a further milestone depends on 2023 revenue. The filing describes a $219 million 2023 target, with partial payment possible at 90% achievement.
- Management’s longer-term strategy emphasizes expanding exome and genome sequencing, growing commercial capacity, and developing Centrellis services for biopharma. The filing provides no specific consolidated revenue or profitability guidance.
- Risks include reimbursement and recoupment uncertainty, adoption and competition, supplier and cloud-provider reliance, regulation of laboratory-developed tests, privacy and cybersecurity, and execution of the exits and integration. The company reported material weaknesses in internal control over financial reporting and concluded disclosure controls were ineffective as of year-end. Management continued remediation efforts; the auditor did not provide an opinion on internal-control effectiveness.
- The filing discloses a shareholder securities class action against the company and certain current and former officers, and a separate CMLS-related stockholder suit in which the company is not a defendant but may face advancement or indemnification claims. The company states it believes the allegations are without merit.
- Nasdaq notified the company in December 2022 that its share price did not meet the $1 minimum bid requirement; the compliance period ran through June 26, 2023. The company planned to seek stockholder approval for a reverse stock split and for issuance of certain offering shares.
Key facts investors should verify
- Cash burn, the post-offering cash position, and whether the stated 12-month liquidity expectation remains supported by operating results and financing access.
- Progress toward improved gross margins and cost reductions after the business exits, including any additional impairment, lease, or restructuring charges.
- GeneDx test volumes, reimbursement and collection rates, and whether the 2023 acquisition milestone target is met.
- Payments and releases under the $42 million payer settlement, and changes in reserves for other payer recoupments.
- Remediation of material weaknesses and the status of Nasdaq listing compliance, including any stockholder approvals.
- Potential dilution from equity offerings, acquisition milestones, warrants, and outstanding equity awards.